Generex Biotechnology Corp. (fka GNBTQ)

[WeeZuhl]

Stoner Dogs Get The Munchies, Indeed

BUCCAL CANNABIS--> Doritos & grape pop-->BUCCAL INSULIN-->REPEAT

GNBT a weed stock? Avoid the undesirable aspects of inhalation and unpredictable results of oral ingestion. Just don't mix up the weed puffer and the insulin puffer. Buccal absorption works, folks. Only question is if management can execute before the lights go out.



http://www.prnewswire.com/news-releases/generex-announces-formalization-of-buccal-cannabis-co-development-plan-300136673.html

Generex Announces Formalization of Buccal Cannabis Co-Development Plan

Contract signed with CannScience Innovations Inc.

WORCESTER, Mass. and TORONTO, Sept. 2, 2015 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that its previously announced intention to implement a buccal cannabis co-development arrangement with CannScience Innovations Inc. (www.cannsci.com) has been formalized.

Generex and CannScience have entered into a binding Co-Development and Technology Licensing Agreement. Pursuant to the Agreement, Generex has licensed its proprietary RapidMist™ drug delivery platform technologies to CannScience for the co-development of products for the buccal delivery of cannabinoids and cannabinoid-derived products and granted an exclusive license to CannScience for the commercialization of such products in Canada in exchange for royalty payments. Generex and CannScience will co-own the intellectual property created by this co-development effort and will share profits from the global commercialization of the products.

CannScience is a research & development biopharmaceutical company established to conduct research, and undertake the development of, therapeutic products based on the extracts from medicinal cannabis. The company is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of medicinal cannabis. CannScience is working on integrating various medical devices and drug delivery technologies for the delivery of medications for various patient populations.

"With this co-development program, Generex and CannScience seek to benefit from the growing global trend towards legalization of cannabis, particularly for medicinal purposes," commented Mark Fletcher, Generex President & Chief Executive Officer. "Our goal here is to develop products combining proprietary formulations and devices for the buccal delivery of dose-specific cannabinoids into the human body with no deposit into the lungs, thereby offering a safe, simple, fast, and efficacious alternative to smoking or edibles with their attendant uncertainties in respect of onset of action and dose control."